@article{f7a4463738a44c2e988395c86a693888,
title = "Editorial: Arthritis Gene Therapy Using Interleukin-1 Receptor Antagonist",
author = "Christopher Evans",
note = "Funding Information: Supported by the NIH (grant X01 NS066865 from the National Center for Advancing Translational Sciences) and the United States Department of Defense (grant PR151990). Christopher Evans, PhD, DSc: Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, Minnesota. Dr. Evans is a cofounder of Genascence Inc. and has received consulting fees and/or honoraria from Orthogen AG (less than $10,000) and Kolon TissueGene (more than $10,000). Address correspondence to Christopher Evans, PhD, DSc, Rehabilitation Medicine Research Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail: Evans.christopher@mayo.edu. Submitted for publication July 9, 2018; accepted July 17, 2018.",
year = "2018",
month = nov,
doi = "10.1002/art.40675",
language = "English (US)",
volume = "70",
pages = "1699--1701",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",
}